Main Article Content
Objective: The objective of the present study is to evaluate the efficacy and safety of two low doses of mifepristone 10 mg and 25 mg in small (< 3 cm) and big myomas (4-6 cm) respectively.
Materials and methods: A total of 30 patients of reproductive age group with fibroids were divided into two groups: Group I (n=15) included women with fibroid size (4-6 cm) and Group II (n=15) included women with small fibroid size (<3 cm). Group I and Group II were administered daily dose of mifepristone as 25mg and 10mg respectively. Statistical analysis was done using SPSS software.
Results: The results of our study demonstrated that 10 mg of mifepristone is as effective as 25 mg/day dose in relieving menorrhagia and reducing myoma volume. However, effect on pain reduction was slightly more pronounced with 25 mg dose of mifepristone as compared to 10 mg dose. Three patients who did not respond satisfactorily to 10 mg dose in the group 2 were escalated to 25 mg daily dose which improved the myoma symptoms and sustained the results (p<0.001). Moreover, there were minimum side effects.
Conclusions: Fibroids, irrespective of the characteristic, whether submucous, intramural or subserous respond very well to mifepristone and disappeared on follow-up on high resolution ultrasound. Twenty-five mg daily dose is preferred over 10mg, irrespective of the size of the fibroid. Mifepristone is an acceptable solution for the medical management of the fibroids upto six cm as it is administered orally, is cost effective with mild side effects.
Keywords: Mifepristone; Fibroids; Leiomyoma